VI Line
-1.73 (-1.41%)
Industry: Diagnostics & Research
30-minutes delayed


Overview Company Info Key Ratios Income Balance Sheet Cash Flow

PerkinElmer's T-Cell Select reagent kit gets FDA approval for automation of T-SPOT.TB test

Trending News

PerkinElmer's T-Cell Select reagent kit has been approved by the US Food and Drug Administration for use in automating the company's T-SPOT.TB test workflow. The kit is designed to reduce hands-on time for laboratory personnel and lower overall costs. In a press release, the...


PerkinElmer gets FDA approval for T-Cell Select kit to automate TB test

  • PerkinElmer's (NYSE:PKI) Oxford Immunotec said that the U.S. Food and Drug Administration (FDA) approved the use of T-Cell Select reagent kit for automation of its T-SPOT.TB test workflow.
  • The T-Cell Select reagent kit...


PerkinElmer, Inc. (PKI) Presents at Baird's 2022 Global Healthcare Conference (Transcript)

PerkinElmer, Inc. (PKI)

Baird’s 2022 Global Healthcare Conference

September 13, 2022 10:50 AM ET

Company Participants

Prahlad Singh - CEO

Conference Call Participants

Tom Peterson -...


PerkinElmer: Focusing, Appealing

Towards the end of February, I concluded that there was a solid diagnosis for PerkinElmer (PKI) as it has seen a real boom following the pandemic. The company has seen strong "organic" performance, as I saw no reason to alter that stance.



PerkinElmer downgraded to hold at Stifel on CFO departure

  • Stifel has downgraded PerkinElmer (NYSE:PKI) from buy to hold following the recent announcement that Jamey Mock is leaving as the company's CFO.
  • The firm also reduced its price target to $170 from $190 (~13% upside...


PerkinElmer names new CFO as Jamey Mock joins Moderna

  • PerkinElmer (NYSE:PKI) announced Wednesday the departure of senior vice president and chief financial officer Jamey Mock as he joins Moderna (MRNA) as its finance chief.
  • The Board of healthcare diagnostics company,...


PerkinElmer, Inc. (PKI) CEO Prahlad Singh on Q2 2022 Results - Earnings Call Transcript

PerkinElmer, Inc. (PKI)

Q2 2022 Earnings Conference Call

August 04, 2022, 08:00 ET

Company Participants

Stephen Willoughby - VP, IR

Prahlad Singh - CEO, President & Director

James Mock - SVP & CFO



PerkinElmer, Inc. 2022 Q2 - Results - Earnings Call Presentation

The following slide deck was published by PerkinElmer, Inc. in conjunction with their 2022 Q2 earnings call.


- SA Transcripts


PerkinElmer Q2 2022 Earnings Preview

  • PerkinElmer (NYSE:PKI) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open.

PerkinElmer retraces gains as BofA downgrades citing valuation

  • Following an earnings-led rally yesterday, the shares of life sciences company PerkinElmer, Inc. (NYSE:PKI) traded lower in the morning hours Tuesday after Bank of America downgraded the stock to Neutral from Buy, citing...


All statements, views or opinions expressed here are the personal views of our users. They do not represent nor should they be construed as representing our statements, views or opinions. For the avoidance of doubt, any such statements, views or opinions are not and shall not be construed as financial advice.

Investing Made Smarter, Faster, Easier for Everyone